scholarly journals Gene Therapy for Infectious Diseases

1998 ◽  
Vol 11 (1) ◽  
pp. 42-56 ◽  
Author(s):  
Bruce A. Bunnell ◽  
Richard A. Morgan
Keyword(s):  
Gene Therapy ◽  
Infectious Diseases ◽  
Infectious Agent ◽  
Catalytic Rna ◽  
Single Chain ◽  
Gene Therapies ◽  
Single Chain Antibodies ◽  
Wide Range ◽  
Management Approaches ◽  
I Gene

SUMMARY Gene therapy is being investigated as an alternative treatment for a wide range of infectious diseases that are not amenable to standard clinical management. Approaches to gene therapy for infectious diseases can be divided into three broad categories: (i) gene therapies based on nucleic acid moieties, including antisense DNA or RNA, RNA decoys, and catalytic RNA moieties (ribozymes); (ii) protein approaches such as transdominant negative proteins and single-chain antibodies; and (iii) immunotherapeutic approaches involving genetic vaccines or pathogen-specific lymphocytes. It is further possible that combinations of the aforementioned approaches will be used simultaneously to inhibit multiple stages of the life cycle of the infectious agent.

scholarly journals Neutralizationof Enteric Coronaviruses with Escherichia coli CellsExpressing Single-Chain Fv-AutotransporterFusions

2003 ◽  
Vol 77 (24) ◽  
pp. 13396-13398 ◽  
Author(s):  
Esteban Veiga ◽  
Víctor de Lorenzo ◽  
Luis Angel Fernández
Keyword(s):  
Escherichia Coli ◽  
Infectious Agent ◽  
Target Cells ◽  
Single Chain ◽  
E Coli ◽  
Single Chain Antibodies ◽  
Single Chain Fv ◽  
Transmissible Gastroenteritis ◽  
Iga Protease

ABSTRACT We report here that fusions of single-chain antibodies (scFvs) to the autotransporter β domain of the IgA protease of Neisseria gonorrhoeae are instrumental in locating virus-neutralizing activity on the cell surface of Escherichia coli. E. coli cells displaying scFvs against the transmissible gastroenteritis coronavirus on their surface blocked in vivo the access of the infectious agent to cultured epithelial cells. This result raises prospects for antiviral strategies aimed at hindering the entry into target cells by bacteria that naturally colonize the same intestinal niches.

Peptide Shuttle-Mediated Delivery for Brain Gene Therapies

2020 ◽  
Vol 20 (32) ◽  
pp. 2945-2958
Author(s):  
Josep Garcia ◽  
Pol Arranz-Gibert ◽  
Macarena Sánchez-Navarro ◽  
Ernest Giralt ◽  
Meritxell Teixidó
Keyword(s):  
Gene Therapy ◽  
Special Focus ◽  
Gene Therapies ◽  
Efficient Gene ◽  
Wide Range ◽  
Monogenic Diseases ◽  
Delivery Strategies ◽  
Inpatient Safety ◽  
Broad Overview

The manipulation of an individual’s genetic information to treat a disease has revolutionized the biomedicine field. Despite the promise of gene therapy, this treatment can have long-term sideeffects. Efforts in the field and recent discoveries have already led to several improvements, including efficient gene delivery and transfer, as well as inpatient safety. Several studies to treat a wide range of pathologies-such as cancer or monogenic diseases- are currently being conducted. Here we provide a broad overview of methodologies available for gene therapy, placing a strong emphasis on treatments for central nervous system diseases. Finally, we give a perspective on current delivery strategies to treat such diseases, with a special focus on systems that use peptides as delivery vectors.

scholarly journals AAV2/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies Inhibits Murine Choroidal Neovascularization

2019 ◽  
Vol 13 ◽  
pp. 86-98 ◽  
Author(s):  
Chris P. Hughes ◽  
Neil M.J. O’Flynn ◽  
Maureen Gatherer ◽  
Michelle E. McClements ◽  
Jennifer A. Scott ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Choroidal Neovascularization ◽  
Single Chain ◽  
Single Chain Antibodies ◽  
Angiogenic Gene

Genetically Engineered Intracellular Single-Chain Antibodies in Gene Therapy

2002 ◽  
Vol 22 (2) ◽  
pp. 191-212 ◽  
Author(s):  
Guadalupe Bilbao ◽  
Juan Luis Contreras ◽  
David T Curiel
Keyword(s):  
Gene Therapy ◽  
Genetically Engineered ◽  
Single Chain ◽  
Single Chain Antibodies

Intracellular Single-Chain Antibodies for Gene Therapy

2003 ◽  
pp. 121-149
Author(s):  
Guadalupe Bilbao ◽  
Jesus Gomez-Navarro ◽  
Keizo Kazano ◽  
Juan Luis Contreras ◽  
David T. Curiel
Keyword(s):  
Gene Therapy ◽  
Single Chain ◽  
Single Chain Antibodies

scholarly journals Crucial and Diverse Role of the Interleukin-33/ST2 Axis in Infectious Diseases

2015 ◽  
Vol 83 (5) ◽  
pp. 1738-1748 ◽  
Author(s):  
Octavie Rostan ◽  
Muhammad Imran Arshad ◽  
Claire Piquet-Pellorce ◽  
Florence Robert-Gangneux ◽  
Jean-Pierre Gangneux ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Infectious Agent ◽  
Lymphoid Cells ◽  
Therapeutic Interventions ◽  
Th2 Cells ◽  
Target Cells ◽  
Protective Effects ◽  
Interleukin 33 ◽  
Wide Range

Interleukin-33 (IL-33) has now emerged as a cytokine with diverse and pleiotropic functions in various infectious and inflammatory diseases. IL-33 is expressed by epithelial cells, endothelial cells, fibroblasts, and hepatocytes. The target cells of IL-33 are Th2 cells, basophils, dendritic cells, mast cells, macrophages, NKT cells, and nuocytes, newly discovered natural helper cells/innate lymphoid cells bearing the ST2 receptor. IL-33 has dual functions, both as a traditional cytokine and as a nuclear factor that regulates gene transcription. IL-33 functions as an “alarmin” released following cell death, as a biomarker, and as a vaccine adjuvant, with proinflammatory and protective effects during various infections. The exacerbated or protective role of the IL-33/ST2 axis during different infections is dependent upon the organ involved, type of infectious agent, whether the infection is acute or chronic, the invasiveness of the infectious agent, the host immune compartment, and cellular and cytokine microenvironments. In this review, we focus on recent advances in the understanding of the role of the IL-33/ST2 axis in various viral, bacterial, fungal, helminth, and protozoal infectious diseases gained from animal models and studies in human patients. The functional role of IL-33 and ST2 during experimentally induced infections has been summarized by accumulating the data for IL-33- and ST2-deficient mice or for mice exogenously administered IL-33. In summary, exploring the crucial and diverse roles of the IL-33/ST2 axis during infections may help in the development of therapeutic interventions for a wide range of infectious diseases.

Evaluation of the nucleopolyhedrovirus of Anticarsia gemmatalis as a vector for gene therapy in mammals

2020 ◽  
Vol 20 ◽  
Author(s):  
Cintia N. Parsza ◽  
Diego L. Mengual Gómez ◽  
Jorge Alejandro Simonin ◽  
Mariano Nicolás Belaich ◽  
Pablo Daniel Ghiringhelli
Keyword(s):  
Gene Therapy ◽  
Mammalian Cells ◽  
Insect Cells ◽  
Autographa Californica ◽  
Anticarsia Gemmatalis ◽  
Agricultural Pests ◽  
Mammalian Cell Lines ◽  
Delivery Vector ◽  
Wide Range ◽  
Insect Pathogens

Background: Baculoviruses are insect pathogens with important biotechnological applications that transcend their use as biological controllers of agricultural pests. One species, Autographa californica multiple nucleopolhyedrovirus (AcMNPV) has been extensively exploited as a molecular platform to produce recombinant proteins and as a delivery vector for genes in mammals, because it can transduce a wide range of mammalian cells and tissues without replicating or producing progeny. Objective/Method: To investigate if the budded virions of Anticarsia gemmatalis multiple nucleopolhyedrovirus (AgMNPV) species has the same ability, the viral genome was modified by homologous recombination into susceptible insect cells to integrate reporter genes and then it was evaluated on mammalian cell lines in comparative form with respect to equivalent viruses derived from AcMNPV. Besides, the replicative capacity of AgMNPV´s virions in mammals was determined. Results: The experiments carried out showed that the recombinant variant of AgMNPV transduces and support the expression of delivered genes but not replicates in mammalian cells. Conclusion: Consequently, this insect pathogen is proposed as an alternative of non-infectious viruses in humans to explore new approaches in gene therapy and other applications based on the use of mammalian cells.

scholarly journals Drivers of Infectious Disease Seasonality: Potential Implications for COVID-19

2021 ◽  
pp. 074873042098732
Author(s):  
N. Kronfeld-Schor ◽  
T. J. Stevenson ◽  
S. Nickbakhsh ◽  
E. S. Schernhammer ◽  
X. C. Dopico ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Infectious Diseases ◽  
Multidisciplinary Approach ◽  
Preliminary Assessment ◽  
Epidemiological Evidence ◽  
Wide Range ◽  
Human Coronaviruses ◽  
Induced Changes ◽  
And Behavior ◽  
Timing Phase

Not 1 year has passed since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). Since its emergence, great uncertainty has surrounded the potential for COVID-19 to establish as a seasonally recurrent disease. Many infectious diseases, including endemic human coronaviruses, vary across the year. They show a wide range of seasonal waveforms, timing (phase), and amplitudes, which differ depending on the geographical region. Drivers of such patterns are predominantly studied from an epidemiological perspective with a focus on weather and behavior, but complementary insights emerge from physiological studies of seasonality in animals, including humans. Thus, we take a multidisciplinary approach to integrate knowledge from usually distinct fields. First, we review epidemiological evidence of environmental and behavioral drivers of infectious disease seasonality. Subsequently, we take a chronobiological perspective and discuss within-host changes that may affect susceptibility, morbidity, and mortality from infectious diseases. Based on photoperiodic, circannual, and comparative human data, we not only identify promising future avenues but also highlight the need for further studies in animal models. Our preliminary assessment is that host immune seasonality warrants evaluation alongside weather and human behavior as factors that may contribute to COVID-19 seasonality, and that the relative importance of these drivers requires further investigation. A major challenge to predicting seasonality of infectious diseases are rapid, human-induced changes in the hitherto predictable seasonality of our planet, whose influence we review in a final outlook section. We conclude that a proactive multidisciplinary approach is warranted to predict, mitigate, and prevent seasonal infectious diseases in our complex, changing human-earth system.

Sign in / Sign up

Export Citation Format

Share Document